Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Harmony Biosciences Holdings Days Payable?
Harmony Biosciences HoldingsHRMY +1.35%94 Days Payable is 36.30 as of Jun. 2026, which is 12% above its 10-year median of 32.39. GuruFocus rates HRMY with a GF Score™ of 94/100 and a GF Value™ of $46.81 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 703 Biotechnology companies, Harmony Biosciences Holdings ranks worse than 72.26% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Harmony Biosciences Holdings's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Harmony Biosciences Holdings Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Harmony Biosciences Holdings's Days Payable distribution charts can be found below:
* The bar in red indicates where Harmony Biosciences Holdings's Days Payable falls into.
Harmony Biosciences Holdings Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Harmony Biosciences Holdings (HRMY) has a Days Payable of 36.30 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Harmony Biosciences Holdings and its competitors. This is 12% above median its historical median of 32.39. Over the past decade, Harmony Biosciences Holdings' Days Payable has ranged from 10.46 to 905.21. According to the industry distribution chart, Harmony Biosciences Holdings ranks #508 out of 703 companies in the Biotechnology industry, placing it in the top 72.3%.
Is Harmony Biosciences Holdings' Days Payable too high?
Harmony Biosciences Holdings' current Days Payable of 36.30 is 12% above median its 10-year median of 32.39. Over the past 10 years, this metric has ranged from a low of 10.46 to a high of 905.21. The Biotechnology industry median Days Payable is 112.84. Harmony Biosciences Holdings' value of 36.30 is 67.8% below this industry median. Based on the distribution chart, Harmony Biosciences Holdings ranks #508 out of 703 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Harmony Biosciences Holdings has a GF Score™ of 94/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Harmony Biosciences Holdings' Days Payable compare to SION and URGN?
According to the Biotechnology industry distribution chart, Harmony Biosciences Holdings ranks #508 out of 703 companies for Days Payable. This places Harmony Biosciences Holdings in the lower half of its industry. The industry median Days Payable is 112.84. Harmony Biosciences Holdings' value of 36.30 is 67.8% below this benchmark. Historically, Harmony Biosciences Holdings' own Days Payable has ranged from 10.46 to 905.21 over the past decade. While the company's 10-year median is 32.39 vs. the industry median of 112.84, Harmony Biosciences Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 703 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Harmony Biosciences Holdings's current Days Payable of 36.30 is 67.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Harmony Biosciences Holdings and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Harmony Biosciences Holdings's current Days Payable is 36.30, which is 12% above median its own 10-year median of 32.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harmony Biosciences Holdings stock overvalued right now?
Based on GuruFocus' analysis, Harmony Biosciences Holdings (HRMY) is currently considered Modestly Undervalued. The stock's GF Value™ is $46.81, compared to a current price of $38.74 — trading 17.2% below its estimated fair value. The current Days Payable is 36.30, which is 12% above median its 10-year median of 32.39 and 67.8% below the Biotechnology industry median of 112.84. Harmony Biosciences Holdings' overall GF Score™ is 94/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Harmony Biosciences Holdings (HRMY), the current Days Payable is 36.30 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Harmony Biosciences Holdings (HRMY) Overvalued in 2026?
Based on GuruFocus' analysis, Harmony Biosciences Holdings stock appears to be undervalued.
The current stock price of $38.74 is trading 17.2% below its estimated GF Value™ of $46.81.
GuruFocus considers Harmony Biosciences Holdings to be Modestly Undervalued.
Key valuation signals for HRMY:
Days Payable: 36.30 (12% above median its 10-year median of 32.39)
GF Value™: $46.81 vs. price of $38.74 (17.2% below fair value)
Industry Position: 67.8% below the Biotechnology median (#508 of 703)
No single metric tells the full story. See the HRMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
94GF Score
Get the complete analysis for HRMY
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HRMY has been successfully added to your 
